Sign in
Back
Fibrates for Primary Biliary Cholangitis: What's All the Hype?
Journal article   Open access  Peer reviewed

Fibrates for Primary Biliary Cholangitis: What's All the Hype?

Cynthia Levy
Annals of hepatology, Vol.16(5), pp.704-706
2017-09
DOI: https://doi.org/10.5604/01.3001.0010.2709
PMID: 28809729

Abstract

Fibric Acids - therapeutic use Off-Label Use Humans Liver Cirrhosis, Biliary - drug therapy Cholangitis - mortality Treatment Outcome Ursodeoxycholic Acid - adverse effects Cholagogues and Choleretics - adverse effects Cholangitis - diagnosis Chenodeoxycholic Acid - analogs & derivatives Cholagogues and Choleretics - therapeutic use Fibric Acids - adverse effects Cholangitis - drug therapy Ursodeoxycholic Acid - therapeutic use Liver Cirrhosis, Biliary - diagnosis Chenodeoxycholic Acid - adverse effects Chenodeoxycholic Acid - therapeutic use Drug Therapy, Combination Liver Cirrhosis, Biliary - mortality
Ursodeoxycholic acid is the first-line therapy for primary biliary cholangitis. However, a subset of patients fail to show biochemical response. For these patients, adjuvant therapies are warranted. Obeticholic acid was conditionally approved as a second-line drug. Evidence is building up in favor of fibrates, which are available for off-label use.
url
https://doi.org/10.5604/01.3001.0010.2709View
Published (Version of record) Open

Metrics

9 Record Views
2 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics
1 Clinical & Life Sciences
1.125 Hepatitis
1.125.1515 Primary Biliary Cirrhosis
Web Of Science research areas
Gastroenterology & Hepatology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details